Key Highlights

  • MEHA shares ticked up 2.27% to $0.0045 at last closing, a move that at this price level reflects thin trading rather than a confirmed catalyst.
  • Functional Brands develops and distributes nutraceutical supplements spanning immunity, sleep, energy, pain and prenatal categories under the long-established Kirkman brand.
  • The company disclosed a Nasdaq delisting determination in June 2026, and its shares now trade over the counter with a market Capitalization in the low hundreds of thousands of dollars.
  • The company has announced a range of new ventures, including a digital-health platform, as it looks to diversify beyond its core supplement business.

Functional Brands, Inc (OTC:MEHA) sits at the speculative edge of the health-and-wellness market, a former Nasdaq hopeful now trading for a fraction of a cent. The nutraceutical and supplement company has spent the past year pushing an ambitious slate of product launches and corporate initiatives, and its shares ticked up 2.27% to $0.0045 at last closing. Its Market Value has shrunk to only a few hundred thousand dollars, and the modest move is best read as one wrinkle in a story that is less about one session and more about a micro-cap fighting for relevance.

Company and Latest Development

Based in West Hollywood, California, Functional Brands develops and distributes nutraceutical supplements spanning immunity, sleep, energy, pain and prenatal categories, and markets products under the long-established Kirkman brand. The company completed a registration process with the U.S. Securities and Exchange Commission in late 2025 and pursued a public listing. In June 2026, it disclosed a Nasdaq delisting determination, and its shares now change hands over the counter. Alongside its core supplement business, the company has announced a range of new ventures, including a digital-health platform and other Diversification efforts.

What Is Driving Attention Around MEHA?

The uptick flagged in price data does not correspond to a single, independently verifiable catalyst. For a stock priced near half a cent with a market capitalization in the low hundreds of thousands of dollars, daily percentage swings are heavily influenced by thin trading Volume and wide bid-ask spreads rather than fundamental news. Attention around MEHA has been driven more by the company's steady stream of announcements and its transition from Nasdaq aspirant to OTC-listed micro-cap than by any confirmed development behind the specific move.

Key Numbers and Company Position

Functional Brands trades around $0.0045 per share, translating to a market capitalization of roughly $320,000. The company has reported Revenue in the mid-single-digit millions on a trailing basis alongside a net loss, underscoring that it remains unprofitable. Its SEC filing history includes numerous S-1 registration amendments through 2025 and current reports into 2026.

What Could Come Next?

Key items to monitor include the company's future SEC filings, any update on its exchange-listing status, and whether its announced product launches and diversification initiatives translate into revenue. Progress or setbacks in its Kirkman-branded supplement lines, its cash position, and any financing activity could all influence sentiment. Because micro-caps of this size often communicate through press releases and periodic filings, disclosures may be irregular and Warrant careful verification.

Risks to Watch

The risks are significant. Sub-penny OTC stocks carry extreme volatility, limited Liquidity and heightened potential for total loss. A delisting from Nasdaq removes the visibility and investor protections of a major exchange. Ongoing net losses raise questions about funding and possible dilution, and an aggressive pace of unrelated announcements can be difficult to assess.

A Micro-Cap Still Proving Its Path Forward

Functional Brands illustrates the precarious position of a small nutraceutical company that reached for a public listing and now trades as a sub-penny OTC name. With a modest revenue base, continuing losses and a delisting behind it, the company's path forward depends on execution in its core supplement lines and clarity from its filings. Investors may be watching SEC disclosures, listing developments and evidence that its many initiatives can produce durable, verifiable results.